计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
N125522-10mg |
10mg |
现货 ![]() |
| |
N125522-50mg |
50mg |
现货 ![]() |
| |
N125522-100mg |
100mg |
现货 ![]() |
| |
N125522-250mg |
250mg |
现货 ![]() |
| |
N125522-1g |
1g |
现货 ![]() |
|
别名 | 5-(1H-吲哚-3-基甲基)-3-甲基-2-硫代-4-咪唑啉酮, 5-(吲哚-3-基甲基)-3-甲基-2-硫代乙内酰脲, MTH-DL-色氨酸 | 5-[(1H-吲哚-3-基)甲基]-3-甲基-2-硫代咪唑啉-4-酮 |
---|---|
英文别名 | 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanyl-3,5-dihydro-4H-imidazol-4-one | 5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo-4-Imidazolidinone | A826160 | HMS3229H21 | CCG-265032 | HY-15760 | Necrostatin 1 | 5-(1H-Indol-3-ylmethyl)-3-methyl-2-thioxoimidazolidin- |
规格或纯度 | Moligand™, ≥99% |
英文名称 | Necrostatin-1 |
生化机理 | Necrostatin-1是坏死性凋亡的抑制剂(非凋亡性细胞死亡途径)。有力的特异性坏死性肾病抑制剂(EC 50 = 490 nM)。死亡域受体相关衔接子激酶RIP1的选择性变构抑制剂体外(EC 50 = 182 nM)。半胱天冬酶独立的程序性坏死途径。 |
储存温度 | -20°C储存,充氩 |
运输条件 | 超低温冰袋运输 |
作用类型 | 抑制剂 |
作用机制 | 吲哚胺 2;3-二氧化酶 1 抑制剂;受体相互作用丝氨酸/苏氨酸激酶 1 抑制剂 |
备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
产品介绍 |
Necrostatin-1has been used to investigate its effect on the regulation of interleukin (IL)-33 expression during liver injury in mice in vivo and in hepatic stellate cells in vitro.It has also been used as an inhibitor of receptor-interacting protein kinase 1 (RIPK1) in experimental studies. Necrostatin-1has been used to investigate its effect on the regulation of interleukin (IL)-33 expression during liver injury in mice in vivo and in hepatic stellate cells in vitro.It has also been used as an inhibitor of receptor-interacting protein kinase 1 (RIPK1) in experimental studies. |
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
PubChem SID | 504762223 |
---|---|
分子类型 | 小分子 |
IUPAC Name | 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylideneimidazolidin-4-one |
INCHI | InChI=1S/C13H13N3OS/c1-16-12(17)11(15-13(16)18)6-8-7-14-10-5-3-2-4-9(8)10/h2-5,7,11,14H,6H2,1H3,(H,15,18) |
InChi Key | TXUWMXQFNYDOEZ-UHFFFAOYSA-N |
Canonical SMILES | CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32 |
Isomeric SMILES | CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32 |
WGK Germany | 3 |
关联CAS | 4311-88-0 |
PubChem CID | 2828334 |
MeSH Entry Terms | Nec-1 compound;necrostatin-1 |
分子量 | 259.33 |
溶解性 | Soluble in DMSO (10-25 mg/ml), 100% ethanol (6 mg/ml), and methanol (5 mg/ml). |
---|---|
敏感性 | 对光线敏感;对空气敏感; 对热敏感 |
熔点 | 160.0 - 164.0 °C |
分子量 | 259.329 g/mol |
XLogP3 | 1.900 |
氢键供体数Hydrogen Bond Donor Count | 2 |
氢键受体数Hydrogen Bond Acceptor Count | 2 |
可旋转键计数Rotatable Bond Count | 2 |
精确质量Exact Mass | 259.078 Da |
单同位素质量Monoisotopic Mass | 259.078 Da |
拓扑极表面积Topological Polar Surface Area | 80.200 Ų |
重原子数Heavy Atom Count | 18 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 373.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 1 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
WGK Germany | 3 |
---|---|
个人防护装备 | Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter |
Purity(HPLC) | 98-100(%) |
---|---|
NMR spectrum | Conforms to Structure |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
批号(Lot Number) | 证书类型 | 日期 | 货号 |
---|---|---|---|
![]() |
分析证书 | 25-01-09 | N125522 |
![]() |
分析证书 | 24-11-21 | N125522 |
![]() |
分析证书 | 24-11-07 | N125522 |
![]() |
分析证书 | 24-04-13 | N125522 |
![]() |
分析证书 | 22-12-14 | N125522 |
![]() |
分析证书 | 22-03-23 | N125522 |
![]() |
分析证书 | 22-03-23 | N125522 |
![]() |
分析证书 | 22-03-23 | N125522 |
![]() |
分析证书 | 22-03-23 | N125522 |
![]() |
分析证书 | 22-03-23 | N125522 |
![]() |
分析证书 | 22-03-23 | N125522 |
1. Yao Li, Jie Wang, Yaru Li, Jiajia Luo, Fang Liu, Tiantian Chen, Yuting Ji, Hong Yang, Zheng Wang, Yanjun Zhao. (2023) Attenuating Uncontrolled Inflammation by Radical Trapping Chiral Polymer Micelles. ACS Nano, [PMID:37352508] [10.1021/acsnano.2c12356] |
1. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X, Abbott D, Cuny GD, Yuan C, Wagner G et al.. (2008) Identification of RIP1 kinase as a specific cellular target of necrostatins.. Nat Chem Biol, 4 (5): (313-21). [PMID:18408713] [10.1021/op500134e] |
2. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA, Yuan J. (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury.. Nat Chem Biol, 1 (2): (112-9). [PMID:16408008] [10.1021/op500134e] |
3. Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB, Goossens V, Roelandt R, Van Hauwermeiren F, Libert C et al.. (2012) Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models.. Cell Death Dis, 3 (13): (e437). [PMID:23190609] [10.1021/op500134e] |
4. Alegre-Cortés E et al.. (2020) Toxicity of Necrostatin-1 in Parkinson's Disease Models.. Antioxidants (Basel), 9 (6): [PMID:32549347] |
5. Li CJ et al.. (2015) \nSynergistic protection of N-acetylcysteine and ascorbic acid 2-phosphate on human mesenchymal stem cells against mitoptosis, necroptosis and apoptosis.\n. Sci Rep, 5 (9819). [PMID:25909282] |
6. Molnár T et al.. (2021) Caspase-9 acts as a regulator of necroptotic cell death.. FEBS J, 288 (22): (6476-6491). [PMID:33899329] |
7. Tsui KH et al.. (2017) DHEA protects mitochondria against dual modes of apoptosis and necroptosis in human granulosa HO23 cells.. Reproduction, 154 (2): (101-110). [PMID:28624766] |
8. Lau H et al.. (2020) Dose-dependent effects of necrostatin-1 supplementation to tissue culture media of young porcine islets.. PLoS One, 15 (12): (e0243506). [PMID:33284818] |
9. Matsuda H et al.. (2017) HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma.. Oncotarget, 8 (41): (69559-69576). [PMID:29050225] |
10. Bockerstett KA et al.. (2018) Interleukin-17A Promotes Parietal Cell Atrophy by Inducing Apoptosis.. Cell Mol Gastroenterol Hepatol, 5 (4): (678-690.e1). [PMID:29930985] |
11. Dallenga T et al.. (2017) M.\xa0tuberculosis-Induced Necrosis of Infected Neutrophils Promotes Bacterial Growth Following Phagocytosis by Macrophages.. Cell Host Microbe, 22 (4): (519-530.e3). [PMID:29024644] |
12. Yan S et al.. (2021) Necroptosis pathway blockage attenuates PFKFB3 inhibitor-induced cell viability loss and genome instability in colorectal cancer cells.. Am J Cancer Res, 11 (5): (2062-2080). [PMID:34094669] |
13. Yan B et al.. (2018) Necrostatin-1 promotes ectopic periodontal tissue like structure regeneration in LPS-treated PDLSCs.. PLoS One, 13 (11): (e0207760). [PMID:30462730] |
14. Lau H et al.. (2019) Necrostatin-1 supplementation enhances young porcine islet maturation and in vitro function.. Xenotransplantation, (e12555). [PMID:31532037] |
15. Lau H et al.. (2021) Necrostatin-1 Supplementation to Islet Tissue Culture Enhances the In-Vitro Development and Graft Function of Young Porcine Islets.. Int J Mol Sci, 22 (16): [PMID:34445075] |
16. Lau H et al.. (2021) The effects of necrostatin-1 on the in vitro development and function of young porcine islets over 14-day prolonged tissue culture.. Xenotransplantation, 28 (3): (e12667). [PMID:33438288] |
17. Trimova G et al.. (2020) Tumour necrosis factor alpha promotes secretion of 14-3-3? by inducing necroptosis in macrophages.. Arthritis Res Ther, 22 (24). [PMID:32051018] |
18. Yao Li, Jie Wang, Yaru Li, Jiajia Luo, Fang Liu, Tiantian Chen, Yuting Ji, Hong Yang, Zheng Wang, Yanjun Zhao. (2023) Attenuating Uncontrolled Inflammation by Radical Trapping Chiral Polymer Micelles. ACS Nano, [PMID:37352508] [10.1021/acsnano.2c12356] |